{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:17:07Z","timestamp":1790612227151,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University","award":["PY2021026"],"award-info":[{"award-number":["PY2021026"]}]},{"name":"Nature Science Foundation for Youths of Jiangsu Province","award":["BK2022043464"],"award-info":[{"award-number":["BK2022043464"]}]},{"name":"Nature Science Foundation for Youths of Jiangsu Province","award":["BK20210962"],"award-info":[{"award-number":["BK20210962"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200210"],"award-info":[{"award-number":["82200210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100207"],"award-info":[{"award-number":["82100207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01003-6","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T16:03:16Z","timestamp":1675526596000},"page":"2651-2662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"23","author":[{"given":"Zhangdi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"issue":"10129","key":"1003_CR1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524\u201337.","journal-title":"Lancet"},{"key":"1003_CR2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","volume":"104","author":"L Scarfo","year":"2016","unstructured":"Scarfo L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169\u201382.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"1003_CR3","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma S, Rai KR. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. Cancer. 2019;125(9):1432\u201340.","journal-title":"Cancer"},{"issue":"6","key":"1003_CR4","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/CCO.0000000000000791","volume":"33","author":"N Albiol","year":"2021","unstructured":"Albiol N, Arguello-Tomas M, Moreno C. The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. Curr Opin Oncol. 2021;33(6):670\u201380.","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"1003_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tcb.2007.02.003","volume":"17","author":"S Hutten","year":"2007","unstructured":"Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol. 2007;17(4):193\u2013201.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"1003_CR6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1\u2014from biology to targeted therapy. Nat Rev Clin Oncol. 2021;18(3):152\u201369.","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"1003_CR7","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","volume":"121","author":"K Kojima","year":"2013","unstructured":"Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121(20):4166\u201374.","journal-title":"Blood"},{"issue":"12","key":"1003_CR8","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","volume":"17","author":"M Ming","year":"2018","unstructured":"Ming M, Wu W, Xie B, et al. XPO1 inhibitor Selinexor overcomes intrinsic Ibrutinib resistance in mantle cell lymphoma via nuclear retention of IkappaB. Mol Cancer Ther. 2018;17(12):2564\u201374.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1003_CR9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.exphem.2012.09.002","volume":"41","author":"K Zhang","year":"2013","unstructured":"Zhang K, Wang M, Tamayo AT, et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013;41(1):67-78e64.","journal-title":"Exp Hematol"},{"issue":"23","key":"1003_CR10","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621\u201334.","journal-title":"Blood"},{"issue":"1","key":"1003_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-020-00373-9","volume":"15","author":"RM Liscic","year":"2020","unstructured":"Liscic RM, Alberici A, Cairns NJ, Romano M, Buratti E. From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline. Mol Neurodegener. 2020;15(1):31.","journal-title":"Mol Neurodegener"},{"issue":"9","key":"1003_CR12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2012-04-423160","volume":"120","author":"P Ranganathan","year":"2012","unstructured":"Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9):1765\u201373.","journal-title":"Blood"},{"key":"1003_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100758","volume":"46","author":"K Benkova","year":"2021","unstructured":"Benkova K, Mihalyova J, Hajek R, Jelinek T. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. Blood Rev. 2021;46: 100758.","journal-title":"Blood Rev"},{"issue":"13","key":"1003_CR14","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed YY. Selinexor: first global approval. Drugs. 2019;79(13):1485\u201394.","journal-title":"Drugs"},{"issue":"10","key":"1003_CR15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/onco.13859","volume":"26","author":"YL Kasamon","year":"2021","unstructured":"Kasamon YL, Price LSL, Okusanya OO, et al. FDA approval summary: selinexor for relapsed or refractory diffuse large B-cell lymphoma. Oncologist. 2021;26(10):879\u201386.","journal-title":"Oncologist"},{"issue":"20","key":"1003_CR16","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","volume":"125","author":"ZA Hing","year":"2015","unstructured":"Hing ZA, Mantel R, Beckwith KA, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 2015;125(20):3128\u201332.","journal-title":"Blood"},{"issue":"25","key":"1003_CR17","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"4","key":"1003_CR18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ijc.2910380413","volume":"38","author":"JV Melo","year":"1986","unstructured":"Melo JV, Brito-Babapulle V, Foroni L, Robinson DS, Luzzatto L, Catovsky D. Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int J Cancer. 1986;38(4):531\u20138.","journal-title":"Int J Cancer"},{"issue":"2","key":"1003_CR19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","volume":"23","author":"A Stacchini","year":"1999","unstructured":"Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999;23(2):127\u201336.","journal-title":"Leuk Res"},{"key":"1003_CR20","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.","journal-title":"Nat Commun"},{"issue":"1","key":"1003_CR21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13045-020-00982-3","volume":"13","author":"M Deng","year":"2020","unstructured":"Deng M, Zhang M, Xu-Monette ZY, et al. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020;13(1):148.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1003_CR22","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.31557\/APJCP.2019.20.12.3747","volume":"20","author":"M Aladhraei","year":"2019","unstructured":"Aladhraei M, Kassem Al-Thobhani A, Poungvarin N, Suwannalert P. Association of XPO1 overexpression with NF-kappaB and Ki67 in colorectal cancer. Asian Pac J Cancer Prev. 2019;20(12):3747\u201354.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"30","key":"1003_CR23","doi-asserted-by":"crossref","first-page":"21289","DOI":"10.18632\/oncotarget.25088","volume":"9","author":"DM Saulino","year":"2018","unstructured":"Saulino DM, Younes PS, Bailey JM, Younes M. CRM1\/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity. Oncotarget. 2018;9(30):21289\u201395.","journal-title":"Oncotarget"},{"issue":"11","key":"1003_CR24","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1002\/ajh.24496","volume":"91","author":"P Jain","year":"2016","unstructured":"Jain P, Kanagal-Shamanna R, Wierda W, et al. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016;91(11):E478\u20139.","journal-title":"Am J Hematol"},{"issue":"7","key":"1003_CR25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","volume":"105","author":"M Yoshimura","year":"2014","unstructured":"Yoshimura M, Ishizawa J, Ruvolo V, et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci. 2014;105(7):795\u2013801.","journal-title":"Cancer Sci"},{"issue":"2","key":"1003_CR26","volume":"416","author":"D Nie","year":"2022","unstructured":"Nie D, Xiao X, Chen J, et al. Prognostic and therapeutic significance of XPO1 in T-cell lymphoma. Exp Cell Res. 2022;416(2): 113180.","journal-title":"Exp Cell Res"},{"key":"1003_CR27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2021.01.008","volume":"503","author":"J Wang","year":"2021","unstructured":"Wang J, Sun T, Meng Z, et al. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Cancer Lett. 2021;503:197\u2013212.","journal-title":"Cancer Lett"},{"issue":"7623","key":"1003_CR28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature19771","volume":"538","author":"J Kim","year":"2016","unstructured":"Kim J, McMillan E, Kim HS, et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 2016;538(7623):114\u20137.","journal-title":"Nature"},{"issue":"1","key":"1003_CR29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian NG, Li Y. XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol. 2020;13(1):61.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1003_CR30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563\u201374.","journal-title":"Blood"},{"key":"1003_CR31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/biomedicines5020027","volume":"5","author":"V Imbert","year":"2017","unstructured":"Imbert V, Peyron JF. NF-kappaB in hematological malignancies. Biomedicines. 2017;5:2.","journal-title":"Biomedicines"},{"issue":"1","key":"1003_CR32","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1038\/s41467-021-23752-2","volume":"12","author":"V Ecker","year":"2021","unstructured":"Ecker V, Stumpf M, Brandmeier L, et al. Targeted PI3K\/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. Nat Commun. 2021;12(1):3526.","journal-title":"Nat Commun"},{"issue":"12","key":"1003_CR33","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","volume":"72","author":"J Bertacchini","year":"2015","unstructured":"Bertacchini J, Heidari N, Mediani L, et al. Targeting PI3K\/AKT\/mTOR network for treatment of leukemia. Cell Mol Life Sci. 2015;72(12):2337\u201347.","journal-title":"Cell Mol Life Sci"},{"issue":"15","key":"1003_CR34","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-16-2632","volume":"23","author":"JS Nair","year":"2017","unstructured":"Nair JS, Musi E, Schwartz GK. Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IkappaB and downregulation of survivin. Clin Cancer Res. 2017;23(15):4301\u201311.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1003_CR35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1535-7163.MCT-18-1319","volume":"19","author":"JA DeSisto","year":"2020","unstructured":"DeSisto JA, Flannery P, Lemma R, et al. Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-kappaB Pathway in preclinical models of pediatric high-grade glioma. Mol Cancer Ther. 2020;19(2):540\u201351.","journal-title":"Mol Cancer Ther"},{"issue":"48","key":"1003_CR36","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","volume":"7","author":"T Kashyap","year":"2016","unstructured":"Kashyap T, Argueta C, Aboukameel A, et al. Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-kappaB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016;7(48):78883\u201395.","journal-title":"Oncotarget"},{"key":"1003_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8900-3_1","volume":"1890","author":"W Link","year":"2019","unstructured":"Link W. Introduction to FOXO biology. Methods Mol Biol. 2019;1890:1\u20139.","journal-title":"Methods Mol Biol"},{"issue":"12","key":"1003_CR38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","volume":"10","author":"I Kapoor","year":"2019","unstructured":"Kapoor I, Li Y, Sharma A, et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 2019;10(12):924.","journal-title":"Cell Death Dis"},{"issue":"15","key":"1003_CR39","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-21-3867","volume":"28","author":"DM Stephens","year":"2022","unstructured":"Stephens DM, Huang Y, Ruppert AS, et al. Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: a phase I study. Clin Cancer Res. 2022;28(15):3242\u20137.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1003_CR40","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/jcmm.13886","volume":"22","author":"DA Luedtke","year":"2018","unstructured":"Luedtke DA, Su Y, Liu S, et al. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. J Cell Mol Med. 2018;22(12):6099\u2013111.","journal-title":"J Cell Mol Med"},{"issue":"9","key":"1003_CR41","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/jcmm.17274","volume":"26","author":"H Yu","year":"2022","unstructured":"Yu H, Wu S, Liu S, et al. Venetoclax enhances DNA damage induced by XPO1 inhibitors: a novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. J Cell Mol Med. 2022;26(9):2646\u201357.","journal-title":"J Cell Mol Med"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01003-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01003-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T17:14:16Z","timestamp":1696094056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01003-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01003-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,4]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital. And written informed consent was obtained from all patients according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}